On this page
HNF1A
HNF1 homeobox A
The HNF1A gene encodes a protein that acts as a transcription factor, playing a crucial role in the development and function of pancreatic beta cells and liver, influencing blood sugar regulation. HNF1A provides instructions for making hepatocyte nuclear factor-1 alpha (HNF-1α), a protein that binds to DNA to control the activity of various genes.
HNF1A is located on the long (q) arm of chromosome 12, at band 12q24.31. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 12 in the library →Overview
The HNF1A gene, formally known as HNF1 homeobox A, is essential for producing the hepatocyte nuclear factor-1 alpha (HNF-1α) protein. This protein acts as a transcription factor, which means it regulates gene expression by binding to specific DNA segments and influencing their activity. Although present in various tissues, HNF-1α holds particular significance in the pancreas and liver.
In the pancreas, HNF-1α is critical for the development and maturation of beta cells. These cells are responsible for synthesising and releasing insulin, a hormone vital for managing blood glucose levels by enabling cells to absorb sugar from the bloodstream for energy. Additionally, the HNF-1α protein controls genes involved in liver development and, through its regulation of cell growth and survival, may function as a tumour suppressor by helping to prevent uncontrolled cellular proliferation.
What the gene does
The HNF-1α protein, synthesised from the HNF1A gene, operates as a transcription factor. This type of protein binds to specific DNA sequences, regulating the rate at which genetic information is transcribed from DNA to messenger RNA. This fundamental regulatory function underpins various cellular processes, including differentiation, growth, and metabolic functions. Its role is especially pronounced in the pancreas, where it influences the development and maturation of beta cells. These cells are crucial for maintaining glucose balance by producing and secreting insulin in response to elevated blood glucose. Appropriate HNF-1α activity ensures adequate insulin production and release, thereby supporting healthy blood sugar management.
Beyond its pancreatic contributions, HNF-1α also plays a part in liver development and function. It regulates genes involved in several hepatic metabolic pathways, affecting processes such as the metabolism of glucose and lipids. The protein's capacity to control genes linked to cell proliferation and survival also suggests a potential role as a tumour suppressor, which implies it can help prevent excessive cellular division. This broad regulatory capability highlights its importance in maintaining metabolic and cellular health.
The functional mechanism of HNF-1α involves its ability to form dimers, where two HNF-1α proteins combine to create a functional unit. This dimer then binds to specific DNA sequences via its DNA-binding domain. The HNF-p1 domain and the N-terminal Dimerization region are essential for facilitating these protein-protein interactions, enabling the formation of homodimers (two HNF-1α proteins) or heterodimers with other similar proteins. Once bound to DNA, the HNF-1α dimer can either activate or repress gene transcription, thereby orchestrating the expression of a complex network of target genes crucial for its diverse physiological roles.
Video: Genetics 101
Chromosome location
The HNF1A gene is found on chromosome 12 at position 12q24.31. This indicates that the gene is located on the long (q) arm of chromosome 12, specifically within band 24 and sub-band 31. The protein encoded by this gene is 631 amino acids in length.
Protein structure
The HNF-1α protein comprises several distinct functional regions and domains that facilitate its role as a transcription factor. At the N-terminus, amino acids 1-32 form the HNF-p1 domain, which overlaps with the Dimerization region spanning amino acids 1-31. This Dimerization region is critical for enabling HNF-1α proteins to interact with each other, forming functional two-protein units (dimers).
Following this, a Disordered region is found from amino acids 40-81. A key functional component, the POU-specific atypical domain, spans amino acids 87-182. Within this POU domain, several Interaction with DNA regions are identified: amino acids 130-132, 143-149, and 155-158, indicating specific contact points with DNA. Another Disordered region follows, from amino acids 183-205, which also contains a Nuclear localization signal motif from amino acids 197-205, crucial for directing the protein to the cell nucleus.
The central part of the protein includes the Homeobox; HNF1-type DNA binding domain, located between amino acids 199-279. This domain is fundamental for the protein's ability to bind to target DNA sequences and regulate gene expression. Additional Interaction with DNA regions are identified within this homeobox domain, specifically at amino acids 203-206, 263-265, and 270-273. Further Disordered regions are present at amino acids 283-358 and 545-567, which may contribute to protein flexibility and interactions with other cellular components.
Key variants
Genetic variants within the HNF1A gene can significantly affect the function of the HNF-1α protein. These changes in the DNA sequence may result in an altered protein structure, reduced protein production, or impair the protein's ability to bind to DNA or form functional dimers. The specific impact of a variant can range from minor alterations in protein activity to a complete loss of function. Pathogenic variants in HNF1A are typically inherited in an autosomal dominant manner, meaning that inheriting just one altered copy of the gene is sufficient to increase the likelihood of developing an associated condition.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
g.4741A>C | - | Pathogenic | ★★★☆ | Maturity-onset diabetes of the young type 3 |
c.598C>T | p.Arg200Trp | Pathogenic | ★★★☆ | Maturity-onset diabetes of the young |
c.1129del | p.Leu377fs | Pathogenic | ★★★☆ | not provided |
c.1136C>G | p.Pro379Arg | Pathogenic | ★★★☆ | not provided |
c.1137del | p.Val380fs | Pathogenic | ★★★☆ | Maturity-onset diabetes of the young type 3 |
c.1137dup | p.Val380fs | Pathogenic | ★★★☆ | Monogenic diabetes |
c.1207del | p.Leu403fs | Pathogenic | ★★★☆ | Monogenic diabetes |
c.121G>T | p.Glu41Ter | Pathogenic | ★★★☆ | Monogenic diabetes |
c.129_130delinsA | p.Leu44fs | Pathogenic | ★★★☆ | Monogenic diabetes |
c.130del | p.Leu44fs | Pathogenic | ★★★☆ | Maturity-onset diabetes of the young type 3 |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Variants in the HNF1A gene are primarily linked to Maturity-Onset Diabetes of the Young (MODY), specifically MODY3 (HNF1A diabetes). This type of diabetes usually develops before the age of 30 and is characterised by unusually high blood glucose levels. Other conditions associated with HNF1A variants include congenital hyperinsulinism, where the pancreas produces excessive insulin, and in some instances, hepatocellular adenomas. These are benign liver tumours that can occur in individuals with HNF1A variants, even without MODY.
Inheritance pattern
Conditions caused by pathogenic HNF1A variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
The HNF1A gene is recognised within the UK's NHS Genomic Medicine Service pathways, reflecting its clinical importance. It is included in several NHS England National Genomic Test Directory panels. For example, it is listed on the 'Congenital hyperinsulinism' panel, the 'Diabetes with additional phenotypes suggestive of a monogenic aetiology' panel, and the 'Familial diabetes' panel. Furthermore, HNF1A is a key gene on the 'Monogenic diabetes' panel, demonstrating its central role in diagnosing and managing inherited forms of diabetes.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
Research indicates that certain lifestyle factors can influence the management and progression of conditions linked to HNF1A variants, such as MODY3. Adopting a balanced diet, often rich in whole grains, lean proteins, fruits, and vegetables, while limiting processed foods and sugary drinks, may assist in controlling blood glucose levels. Regular physical activity generally benefits metabolic health and can contribute to improved glucose control. Maintaining a healthy body weight is also often advised, as obesity can worsen insulin resistance and complicate blood sugar management. However, these are general health recommendations, and individuals with HNF1A variants should consult their healthcare provider for personalised advice on lifestyle adjustments.
Supplement considerations
There is no conclusive evidence that specific supplements can prevent or cure conditions associated with HNF1A variants. Some research has explored the role of various nutrients in metabolic health, such as magnesium supplementation for its potential to improve insulin sensitivity in the general population. However, direct benefits for individuals with HNF1A-related conditions are not definitively established. Similarly, vitamin D has been linked to glucose metabolism, but further studies are needed to determine its efficacy specifically for HNF1A-related diabetes. It is crucial to remember that any decisions regarding dietary supplements should be made in consultation with a healthcare professional, as supplements can interact with medications or have other health implications. There is no evidence to suggest that supplements can replace prescribed medical treatments for HNF1A-related conditions.
Frequently asked questions
What is the HNF1A gene?
The HNF1A gene provides instructions for making a protein called hepatocyte nuclear factor-1 alpha (HNF-1α). This protein acts as a transcription factor, controlling the activity of other genes, particularly in the pancreas and liver.
What does the HNF-1α protein do?
The HNF-1α protein regulates genes important for the development and function of pancreatic beta cells, which produce insulin. It also plays a role in liver development and glucose metabolism, helping to maintain stable blood sugar levels.
Which conditions are associated with HNF1A variants?
Pathogenic variants in the HNF1A gene are primarily associated with Maturity-Onset Diabetes of the Young (MODY), specifically MODY3 (HNF1A diabetes). It can also be linked to congenital hyperinsulinism and certain liver tumours called hepatocellular adenomas.
How is MODY3 inherited?
MODY3, caused by HNF1A variants, is typically inherited in an autosomal dominant pattern. This means that only one altered copy of the HNF1A gene is sufficient to increase the likelihood of developing the condition.
Can lifestyle changes help manage conditions related to HNF1A?
While lifestyle changes such as a balanced diet, regular exercise, and maintaining a healthy weight can generally support metabolic health, individuals with HNF1A-related conditions should consult a healthcare professional for personalised advice and treatment plans.
Is HNF1A relevant to UK clinical practice?
Yes, the HNF1A gene is included in several NHS England National Genomic Test Directory panels, such as those for 'Monogenic diabetes' and 'Congenital hyperinsulinism,' indicating its importance in UK clinical diagnostics for inherited conditions.
References
- Fu J, Wang T, Zhai X. Primary hepatocellular adenoma due to biallelic HNF1A mutations and its co-occurrence with MODY 3: case-report and review of the literature. Endocrine. 2020. PMID: 31754975
- Malikova J, Kaci A, Dusatkova P. Functional Analyses of HNF1A-MODY Variants Refine the Interpretation of Identified Sequence Variants. The Journal of clinical endocrinology and metabolism. 2020. PMID: 32017842
- Haliyur R, Tong X, Sanyoura M. Human islets expressing HNF1A variant have defective β cell transcriptional regulatory networks. The Journal of clinical investigation. 2019. PMID: 30507613
- Najmi LA, Aukrust I, Flannick J. Functional Investigations of HNF1A Identify Rare Variants as Risk Factors for Type 2 Diabetes in the General Population. Diabetes. 2017. PMID: 27899486
- Balamurugan K, Bjørkhaug L, Mahajan S. Structure-function studies of HNF1A (MODY3) gene mutations in South Indian patients with monogenic diabetes. Clinical genetics. 2016. PMID: 26853433
- Yamagata K. Roles of HNF1α and HNF4α in pancreatic β-cells: lessons from a monogenic form of diabetes (MODY). Vitamins and hormones. 2014. PMID: 24559927
- Bluteau O, Jeannot E, Bioulac-Sage P. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nature genetics. 2002. PMID: 12355088